Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Nathan

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|June 11, 2016
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialDavid Cella, Viktor Grünwald, Paul Nathan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2012
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancerThomas Powles, Naveed Sarwar, Rob Jones, et al.
European Urology|November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be AnsweredGrant D Stewart, Michael Aitchison, Axel Bex, et al.
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Journal for Immunotherapy of Cancer|August 17, 2019
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018Paolo A Ascierto, Lisa H Butterfield, Sandra Demaria, et al.
Clinical Genitourinary Cancer|August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study ResultsPaul Nathan, Balaji Venugopal, Jamshed Ali, et al.
European Urology Focus|September 19, 2019
A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal UltrasoundSabrina H Rossi, Tobias Klatte, Juliet A Usher-Smith, et al.
The Lancet. Oncology|January 20, 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialDavid Cella, Viktor Grünwald, Bernard Escudier, et al.
Clinical Genitourinary Cancer|October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell CarcinomaCora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II studyPeter Mulders, Robert Hawkins, Paul Nathan, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|June 11, 2016
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialDavid Cella, Viktor Grünwald, Paul Nathan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2012
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancerThomas Powles, Naveed Sarwar, Rob Jones, et al.
European Urology|November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be AnsweredGrant D Stewart, Michael Aitchison, Axel Bex, et al.
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Journal for Immunotherapy of Cancer|August 17, 2019
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018Paolo A Ascierto, Lisa H Butterfield, Sandra Demaria, et al.
Clinical Genitourinary Cancer|August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study ResultsPaul Nathan, Balaji Venugopal, Jamshed Ali, et al.
European Urology Focus|September 19, 2019
A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal UltrasoundSabrina H Rossi, Tobias Klatte, Juliet A Usher-Smith, et al.
The Lancet. Oncology|January 20, 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialDavid Cella, Viktor Grünwald, Bernard Escudier, et al.
Clinical Genitourinary Cancer|October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell CarcinomaCora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II studyPeter Mulders, Robert Hawkins, Paul Nathan, et al.
Pageof 13